Bristol Myers Squibb has announced the US$4.8 billion acquisition of US company Mirati Therapeutics, under which it will gain rights to a new lung cancer medicine.
BMS secures new cancer therapy with acquisition of Mirati Therapeutics
October 10, 2023 Latest NewsBioPharma
Latest Video
New Stories
-
BCAL advances early cancer detection portfolio as Australian launch looms
November 19, 2025 - - Australian Biotech -
Minister managing the 'double-whammy' of participant and plan growth
November 19, 2025 - - Latest News -
Is this disconnect so entrenched we can no longer recognise the presence of a problem?
November 19, 2025 - - Latest News -
Tryp advances psilocin trial for binge eating disorder as second patient enrolled
November 18, 2025 - - Australian Biotech -
Nyrada advances toward Phase 2a trial of cardioprotective candidate
November 18, 2025 - - Australian Biotech -
We know they're planning something on these issues, because they told us
November 18, 2025 - - Latest News -
The need to honour a strong history while ensuring the future is guided by the 'good guys'
November 17, 2025 - - Latest News